Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin

Abstract EN

Nonmyeloablative (NMA) conditioning with total lymphoid irradiation and antithymocyte globulin (TLI/ATG) has been shown to protect against acute graft-versus-host disease (GVHD).

We report here our institutional experience with allogeneic transplantation following NMA conditioning with TLI/ATG (n=21).

GVHD prophylaxis consisted of a combination of a calcineurin inhibitor and mycophenolate mofetil.

Median patient age was 59 years.

The median followup of surviving patients is 545 days.

One patient experienced primary graft rejection.

The median time to neutrophil engraftment was 18 days and platelet engraftment was 9.5 days.

The cumulative incidence (CI) of grade II–IV acute GVHD at day +100 was 28.6% and 38.1% at day +180.

The CI for grade III-IV acute GVHD was 28.6% at day +180.

CI of chronic GVHD was 45.2% at 1 year.

The CI of disease relapse was 9.5% at 1 year.

The rate of nonrelapse mortality (NRM) was 0% at day +100 and only 9.5% at 1 year.

The overall and progression free survival at 1 year was 81% and 80.4%, respectively.

Our limited, retrospective data show encouraging relapse and NRM rates with TLI/ATG-based NMA conditioning, but with higher than previously reported rates of acute and chronic GVHD, underscoring the need for novel strategies designed to effectively prevent GVHD.